Literature DB >> 26113681

Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension.

Rozenn Quarck1, Marijke Wynants2, Erik Verbeken3, Bart Meyns4, Marion Delcroix5.   

Abstract

Deficient angiogenesis and systemic inflammation could be involved in the pathophysiology of chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to characterise the histopathology of pulmonary vascular lesions from 52 CTEPH patients who underwent a pulmonary endarterectomy (PEA) and investigate a potential link between clinical, biological and morphometric parameters.Collagen, elastin, fibrin, lipid, endothelial, smooth muscle and inflammatory cell content was investigated using immunohistochemistry. Qualitative changes were evaluated using severity scores. Circulating levels of inflammatory mediators were measured using ELISA.Neointima, thrombotic, recanalised and atherosclerotic lesions were found. Accumulation of macrophages, T-lymphocytes and neutrophils was found mainly in atherosclerotic and thrombotic lesions. Angiogenesis was observed in all kinds of lesions; low-scored angiogenesis predicted adverse outcome, including persistent pulmonary hypertension post-PEA, start of medical therapy and poor survival. C-reactive protein (CRP), interleukin-10, monocyte chemotactic protein-1, macrophage inflammatory protein-1α and matrix metalloproteinase (MMP)-9 were significantly elevated in CTEPH patients. Plasma CRP and MMP-9 levels correlated with neutrophil and macrophage accumulation, respectively.Enhanced systemic inflammation parallels local inflammatory cell infiltration in major pulmonary arteries at advanced stages of CTEPH. Impaired neovascularisation is associated with poor survival, start of medical treatment and persistent pulmonary hypertension post-PEA. These findings suggest that inflammation and impaired angiogenesis could contribute to the progression of the disease.
Copyright ©ERS 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26113681     DOI: 10.1183/09031936.00009914

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  38 in total

1.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Chronic Embolic Pulmonary Hypertension Caused by Pulmonary Embolism and Vascular Endothelial Growth Factor Inhibition.

Authors:  Evandro M Neto-Neves; Mary B Brown; Maria V Zaretskaia; Samin Rezania; Adam G Goodwill; Brian P McCarthy; Scott A Persohn; Paul R Territo; Jeffrey A Kline
Journal:  Am J Pathol       Date:  2017-02-07       Impact factor: 4.307

3.  Increased systemic arterial stiffness in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Monika Sznajder; Olga Dzikowska-Diduch; Katarzyna Kurnicka; Marek Roik; Dominik Wretowski; Piotr Pruszczyk; Maciej Kostrubiec
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

Review 4.  Chronic Thromboembolic Pulmonary Hypertension: the Bench.

Authors:  George A Alba; Deepak Atri; Sriranjani Darbha; Inderjit Singh; Victor F Tapson; Michael I Lewis; Hyung J Chun; Yen-Rei Yu; Bradley A Maron; Sudarshan Rajagopal
Journal:  Curr Cardiol Rep       Date:  2021-08-19       Impact factor: 2.931

Review 5.  Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.

Authors:  David S Poch; William R Auger
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 6.  Challenges and opportunities in treating inflammation associated with pulmonary hypertension.

Authors:  Norbert F Voelkel; Rasa Tamosiuniene; Mark R Nicolls
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-05-04

Review 7.  Epidemiology and Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: Risk Factors and Mechanisms.

Authors:  Sarah Medrek; Zeenat Safdar
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

Review 8.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

9.  Neutrophil Extracellular Traps in Atherosclerosis and Thrombosis.

Authors:  Thomas M Hofbauer; Anna S Ondracek; Irene M Lang
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension.

Authors:  Wenyi Pang; Zhu Zhang; Yunxia Zhang; Meng Zhang; Ran Miao; Yuanhua Yang; Wanmu Xie; Jun Wan; Zhenguo Zhai; Chen Wang
Journal:  J Thromb Thrombolysis       Date:  2020-11-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.